» Articles » PMID: 12670345

Treatment with Short-term, High-dose Cyclosporin A in Children with Refractory Chronic Idiopathic Thrombocytopenic Purpura

Overview
Journal Br J Haematol
Specialty Hematology
Date 2003 Apr 3
PMID 12670345
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

We report on 14 children (seven boys, seven girls) with chronic idiopathic thrombocytopenic purpura (ITP) refractory to multiple treatments, who were given a short-term therapy (range between 6 and 10 weeks) with high doses of cyclosporin A (CyA) (median, 10 mg/kg/d). Six patients experienced adverse events and one developed severe systemic mycosis during therapy. A complete response (CR) was observed in four patients and a partial response (PR) in three patients. Only the four CR patients, who were all girls, had a sustained response. These data suggest that CyA may be effective in some children with chronic symptomatic ITP.

Citing Articles

Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers.

Fattizzo B, Cantoni S, Giannotta J, Bandiera L, Zavaglia R, Bortolotti M Ther Adv Hematol. 2022; 13:20406207221097780.

PMID: 35585968 PMC: 9109490. DOI: 10.1177/20406207221097780.


American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Neunert C, Terrell D, Arnold D, Buchanan G, Cines D, Cooper N Blood Adv. 2019; 3(23):3829-3866.

PMID: 31794604 PMC: 6963252. DOI: 10.1182/bloodadvances.2019000966.


Refractory immune thrombocytopenia. Successful treatment with repeated cyclosporine A: two case reports.

Hlusi A, Szotkowski T, Indrak K Clin Case Rep. 2015; 3(6):337-41.

PMID: 26185623 PMC: 4498837. DOI: 10.1002/ccr3.182.


Clinical observation on the treatment of childhood refractory idiopathic thrombocytopenic purpura with Dihuang Zhixue Capsule.

Liu Q, Wu W, Wu D, Feng X, Ma Y, Li J Chin J Integr Med. 2008; 14(2):132-6.

PMID: 18679605 DOI: 10.1007/s11655-008-0132-2.


Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.

Parodi E, Nobili B, Perrotta S, Matarese S, Russo G, Licciardello M Int J Hematol. 2006; 84(1):48-53.

PMID: 16867902 DOI: 10.1532/IJH97.E0518.